Payment overview · 2025
General Payments
$192.17
9 reported records · 8 companies
Healthcare provider profile · identity verified
Keith B Banton, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PANAMA CITY, FL · NPI 1205896636
Verified facts
What the public records show
CMS Open Payments records show Keith B Banton, M.D. received $192.17 in general payments during 2025 across 9 reported records.
Takeda Pharmaceuticals U.S.A., Inc. accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Ozempic, Rybelsus, Trelegy Ellipta, Trintellix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 275 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $33.56 | 17.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.98 | 15.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.05 | 14.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $22.18 | 11.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.01 | 11.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.99 | 10.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.08 | 9.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.32 | 9.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $192.17 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $33.56 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $28.98 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.05 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 275 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 56 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 118 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 113 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
275 | 44 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
118 | 23 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
113 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 618 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 558 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 520 | 79 |
| Losartan Potassium | Losartan Potassium | 512 | 113 |
| Famotidine | Famotidine | 478 | 79 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 397 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 375 | 89 |
| Alprazolam | Alprazolam | 368 | 75 |
| Furosemide | Furosemide | 338 | 68 |
| Carvedilol | Carvedilol | 318 | 75 |
| Tizanidine Hcl | Tizanidine Hcl | 280 | 89 |
| Farxiga | Dapagliflozin Propanediol | 275 | 44 |
| Eliquis | Apixaban | 267 | 42 |
| Atorvastatin Calcium | Atorvastatin Calcium | 259 | 51 |
| Potassium Chloride | Potassium Chloride | 257 | 56 |
| Levetiracetam | Levetiracetam | 247 | 19 |
| Omeprazole | Omeprazole | 227 | 45 |
| Metformin Hcl | Metformin Hcl | 223 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 205 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 202 | 46 |
| Simvastatin | Simvastatin | 191 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 188 | 40 |
| Montelukast Sodium | Montelukast Sodium | 188 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 169 | 78 |
| Trazodone Hcl | Trazodone Hcl | 163 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 162 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 43 |
| Divalproex Sodium | Divalproex Sodium | 143 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 143 | 22 |
| Sertraline Hcl | Sertraline Hcl | 134 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 130 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 125 | 18 |
| Lactulose | Lactulose | 121 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 118 | 23 |
| Trintellix | Vortioxetine Hydrobromide | 113 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 102 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 101 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 19 |
| Mounjaro | Tirzepatide | 98 | 19 |
| Mupirocin | Mupirocin | 98 | 55 |
| Jardiance | Empagliflozin | 95 | 11 |
| Diazepam | Diazepam | 92 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 91 | 26 |
| Xarelto | Rivaroxaban | 91 | suppressed |
| Lisinopril | Lisinopril | 90 | 22 |
| Baclofen | Baclofen | 88 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 88 | 54 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 87 | 16 |
| Sucralfate | Sucralfate | 87 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 86 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | suppressed |
| Haloperidol | Haloperidol | 84 | 24 |
| Amoxicillin | Amoxicillin | 83 | 53 |
| Promethazine Hcl | Promethazine Hcl | 82 | 11 |
| Fluconazole | Fluconazole | 81 | 30 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 77 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 76 | 13 |
| Allopurinol | Allopurinol | 75 | 17 |
| Lamotrigine | Lamotrigine | 74 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 12 |
| Januvia | Sitagliptin Phosphate | 71 | suppressed |
| Valsartan | Valsartan | 70 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 17 |
| Lacosamide | Lacosamide | 66 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 66 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 66 | 16 |
| Spironolactone | Spironolactone | 66 | 17 |
| Tramadol Hcl | Tramadol Hcl | 66 | 12 |
| Ztlido | Lidocaine | 66 | 23 |
| Finasteride | Finasteride | 65 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 17 |
| Meloxicam | Meloxicam | 64 | 13 |
| Oxcarbazepine | Oxcarbazepine | 64 | suppressed |
| Trulicity | Dulaglutide | 63 | suppressed |
| Entresto | Sacubitril/Valsartan | 59 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 59 | 28 |
| Kerendia | Finerenone | 56 | 12 |
| Midodrine Hcl | Midodrine Hcl | 56 | 13 |
| Clonazepam | Clonazepam | 55 | suppressed |
| Ondansetron Odt | Ondansetron | 52 | 14 |
| Clonidine Hcl | Clonidine Hcl | 51 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 50 | suppressed |
| Linzess | Linaclotide | 50 | suppressed |
| Nitroglycerin | Nitroglycerin | 49 | 14 |
| Novolog Flexpen | Insulin Aspart | 49 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 33 |
| Ozempic | Semaglutide | 44 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Digoxin | Digoxin | 42 | 11 |
| Pregabalin | Pregabalin | 42 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 41 | suppressed |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Lovastatin | Lovastatin | 39 | suppressed |
| Methocarbamol | Methocarbamol | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 23 |
| Olanzapine | Olanzapine | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Carbamazepine | Carbamazepine | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 11 |
| Risperidone | Risperidone | 33 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 31 | suppressed |
| Zonisamide | Zonisamide | 31 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Prednisone | Prednisone | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Phenobarbital | Phenobarbital | 28 | suppressed |
| Azithromycin | Azithromycin | 26 | 22 |
| Cefuroxime | Cefuroxime Axetil | 26 | 22 |
| Glimepiride | Glimepiride | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 25 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Verquvo | Vericiguat | 23 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 22 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Phenytoin | Phenytoin | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Permethrin | Permethrin | 17 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Klor-Con 10 | Potassium Chloride | 16 | suppressed |
| Lamotrigine Er | Lamotrigine | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 11 |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Clozapine | Clozapine | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 14 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | 12 |
| Droxidopa | Droxidopa | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Nucynta Er | Tapentadol Hcl | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Clobazam | Clobazam | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Hydrocortisone Valerate | Hydrocortisone Valerate | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $192.17 · 9 records | Takeda Pharmaceuticals U.S.A., Inc. | AUSTEDO XR, Cologuard Collection Kit, FARXIGA, Kerendia, LEQVIO, Ozempic, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error